Cemdisiran
- Generic Name
- Cemdisiran
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1639264-46-2
- Unique Ingredient Identifier
- S66Z65E10T
- Background
Cemdisiran is under investigation in clinical trial NCT03841448 (A Study of Cemdisiran in Adults With Immunoglobulin a Nephropathy (Igan)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- Conditions
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 750
- Registration Number
- NCT06541704
- Locations
- πΊπΈ
Colorado Retina - Lakewood, Lakewood, Colorado, United States
πΊπΈGeorgia Retina - Marietta, Marietta, Georgia, United States
πΊπΈPalmetto Retina Center, West Columbia, South Carolina, United States
Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06028594
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works.
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 202
- Registration Number
- NCT05744921
- Locations
- π¨π³
Chang Gung Memorial Hospital- Linkou Branch, Taoyuan, Taiwan
π¨π¦Toronto General Hospital, Toronto, Ontario, Canada
ππΊSemmelweis University/Semmelweis Egyetem, Budapest, Hungary
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 190
- Registration Number
- NCT05133531
- Locations
- π΅πͺ
Clinica San Felipe, Lima, Peru
π΅πSt Lukes Medical Center, Quezon City, Central Luzon, Philippines
π¨π³Taichung Veterans General Hospital (VGHTC), Taichung City, Taiwan
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05131204
- Locations
- πΊπΈ
Regeneron Research Facility, Whittier, California, United States
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 235
- Registration Number
- NCT05070858
- Locations
- πΊπΈ
HonorHealth Neurology 2018, Scottsdale, Arizona, United States
πΊπΈUniversity of California Irvine, Irvine, California, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT04940364
- Locations
- π¬π§
Regeneron Research Site, London, United Kingdom
Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT04888507
- Locations
- π¬π§
Regeneron Study Site, Leeds, United Kingdom
Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04811716
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
π²πΎHospital Sibu, Sibu, Sarawak, Malaysia
π°π·Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04601844
- Locations
- π§πͺ
Regeneron Research Site, Antwerp, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.